FDA approves Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C infection FDA approved EpclusaTM (sofosbuvir and velpatasvir, (SOF-VEL) for adults with chronic hepatitis C infection both with compensated cirrhosis or without cirrhosis as well as in combination with ribavirin for hepatitis C with decompensated cirrhosis. Update on Diabetes Therapy November 10, 2016 By Monica Shah PharmD Despite evidence that optimal glycemic control can help reduce disease progression and complications, most patients do not achieve recommended treatment goals. Study Finds Oral Syringes Better for Liquid Pediatric Meds November 10, 2016 By Valerie DeBenedette A randomized controlled study has found that oral syringes are more accurate than dosing cups when parents measure doses of liquid medications for their children. Pharmacist involvement key in heart risk screening November 02, 2016 By Christine Blank Pharmacists’ involvement in cardiovascular risk screening resulted in referrals to physicians for patients who were under-diagnosed. Eligible infants not getting rotavirus vaccine November 01, 2016 By Christine Blank Researchers found that estimated coverage for RV at 19 to 35 months of age lags behind the other vaccines recommended at ages two, four, and six. Why Remicade biosimilar sales will grow in the U.S. October 31, 2016 By Christine Blank Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions. What executives must know to combat rising drug spend In today’s healthcare landscape, few things better define the role of a managed healthcare executive than managing the industry’s constant changes. The Power of a Name October 09, 2016 By Jill Sederstrom A new study suggests that the name of a biosimilar product could influence pharmacist confidence levels when dispensing a biosimilar in place of a reference biologic. A Triple Hitter in One Blast: COPD Lessons from TRILOGY Patients with severe COPD are likely to suffer frequent disease exacerbations and a reduced quality of life.